Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Oxaliplatin, a third-generation platinum-based antineoplastic agent, is widely recognized for its pivotal role in the treatment of colorectal cancer. With the chemical formula C8H14N2O4Pt and the CAS number 61825-94-3, this compound belongs to the class of DNA-damaging drugs that function through unique mechanisms distinct from earlier generations like cisplatin and carboplatin. Its molecular structure features a cyclohexane-1,2-diamine ligand coordinated to a platinum center, which facilitates rapid cellular uptake and subsequent formation of intra-strand and inter-strand DNA cross-links. These cross-links distort the DNA helix, effectively inhibiting DNA replication and transcription, ultimately triggering apoptosis in rapidly dividing tumor cells.
Clinically, Oxaliplatin is primarily indicated for the adjuvant treatment of stage III colon cancer following complete resection of the primary tumor, as well as for metastatic colorectal cancer in combination with fluorouracil (5-FU) and leucovorin. It has demonstrated significant efficacy in improving overall survival rates when used in first-line and second-line settings. The drug is typically administered intravenously due to its poor oral bioavailability. While highly effective, its use is associated with specific side effects, most notably dose-dependent peripheral sensory neuropathy, which can manifest as cold-induced paresthesia or dysesthesia. Other common adverse reactions include myelosuppression, nausea, vomiting, and fatigue. Unlike some other platinum agents, it exhibits low levels of nephrotoxicity and ototoxicity, making it a preferred choice in many chemotherapy regimens. Ongoing research continues to explore its potential applications in other malignancies, including gastric and pancreatic cancers, further solidifying its status as a cornerstone therapy in modern oncology. Its mechanism of action remains a subject of intense study to optimize dosing schedules and minimize toxicity while maximizing therapeutic outcomes for patients worldwide.